100 studies found for:    Open Studies | "Vasculitis"
Show Display Options
Rank Status Study
21 Not yet recruiting Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Intervention: Other: Follow-up
22 Recruiting Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
Conditions: Takayasu's Arteritis;   Giant Cell Arteritis;   Arteritis;   Vasculitis;   Aortitis
Intervention:
23 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
24 Recruiting Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA);   Microscopic Polyangiitis (MPA)
Interventions: Procedure: Plasma Exchange;   Drug: Glucocorticoids
25 Recruiting Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
Conditions: Arthritis, Rheumatoid;   Spondylarthritis;   Vasculitis
Intervention: Biological: Hepatitis A vaccine and tetanus vaccine
26 Not yet recruiting BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Blisibimod;   Drug: Placebo
27 Not yet recruiting Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
Conditions: Granulomatosis With Polyangiitis (Wegener's);   Granulomatosis With Polyangiitis;   Wegener's Granulomatosis;   ANCA-Associated Vasculitis
Interventions: Drug: Abatacept;   Drug: placebo
28 Recruiting GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Conditions: Lupus Erythematosus, Systemic;   Systemic Vasculitis;   Isolated Angiitis of Central Nervous System;   Lung Disease With Systemic Sclerosis;   Lung Disease Interstitial Diffuse
Interventions: Drug: depot leuprolide acetate 3.75 mg;   Drug: Placebo
29 Unknown  Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB)
Conditions: Behcet's Disease;   Panuveitis;   Posterior Uveitis;   Retinal Vasculitis
Interventions: Drug: Cyclosporin A;   Drug: Interferon-alpha2a
30 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
31 Recruiting Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Conditions: Autoimmune Disease;   Vascular Disease
Intervention:
32 Recruiting Resistance Exercise in Rheumatic Disease
Conditions: Rheumatoid Arthritis;   Systemic Vasculitis
Intervention: Other: Resistance Exercise
33 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
34 Not yet recruiting Phase Ib Study of SC Milatuzumab in SLE
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic;   Lupus Vasculitis, Central Nervous System;   Lupus Nephritis
Intervention: Drug: milatuzumab
35 Not yet recruiting PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
Conditions: Cardiac Disease;   Dementia;   Inflammatory Disease;   Fever of Unknown Origin;   Vasculitis;   Osteomyelitis;   FDG Avid Cancers
Interventions: Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
36 Unknown  Improving the Quality of Patient Care by Using a Clinical Expert System.
Conditions: Hypertension;   Diabetes;   Hypercholesterolemia;   Vasculitis;   Coronary Heart Diseases
Intervention: Procedure: Computer-assisted history
37 Recruiting The CARRA Registry
Conditions: Juvenile Idiopathic Arthritis;   Systemic Lupus Erythematosus;   Mixed Connective Tissue Disease;   Juvenile Ankylosing Spondylitis;   Juvenile Dermatomyositis;   Localized Scleroderma;   Systemic Sclerosis;   Vasculitis;   Sarcoid;   Fibromyalgia, Primary;   Auto-inflammatory Disease;   Idiopathic Uveitis Idiopathic
Intervention:
38 Recruiting Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
Conditions: Hepatitis C;   Lichen Planus;   Vasculitis;   Autoimmune Diseases
Interventions: Drug: Ribavirin;   Drug: Betamethasone
39 Recruiting Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections
Conditions: RA;   SLE;   Vasculitis;   Scleroderma;   Sjögrens;   Syndrome
Interventions: Biological: 0,5 mg Prevenar i.m.;   Biological: 0,5 mg seasonal influenza vaccine i.m.
40 Recruiting PRO Development for ANCA Associated Vasculitis
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years